Our Services
Clinical Trial Management Services
Central Laboratory Services
Clinical Pharmacology
Scintigraphy
Pharmacovigilance
Regulatory Affairs
Clinical & Medical Writing
Clinical Trial Management Services
Phase I
Phase II
Phase III
Site Management & Monitoring
IMP Management
Biometric Services
Simbec-Orion worked with Faron Pharmaceuticals Ltd. in this phase I/II first-in-human in patients with advanced solid tumours, studying the effect of FP-1305. Analysis of circulating immune cells after administration of the compound demonstrates Th1 activation as well as mobilization of NK cells and B cells. It showed promising tolerability and clinical anti-tumour activity.
